HUM
NYSEVantage displays two distinct quantitative intelligence signals: Cross-Sectional Rank (4-Factor) ranks hum (unranked) (aligning with /picks), while Fundamental Grade (6-Factor) grades standalone business quality & growth from SEC EDGAR filings — valuation, growth, profitability (margin · ROE · ROIC), momentum and EPS revisions (Grade —, Score —/100), with no Wall Street sell-side consensus on file to confirm or contradict it.
Prioritize business quality, pricing power, and valuation multiples. Valuation and quality inputs are not available for this symbol, so no valuation conclusion is drawn here.
Prioritize relative cross-sectional momentum across 2,714 equities. Hold position or wait for momentum confirmation before initiating swing longs.
Cross-sectional 4-factor engine (Valuation, Growth, Quality, Momentum) ranking hum against all 2,714 U.S. equities simultaneously. Answers: “Where does this stock rank relative to the entire market?” Direct parity with Vantage Picks.
Forensic standalone analysis of SEC EDGAR financial statements, ROIC, operating margin stability, and valuation. Answers: “Is this underlying business elite?”
Consensus of institutional sell-side analysts covering forward earnings and price targets.
Why Two Vantage Scores? Vantage separates Market Standing (⚡ Swing Horizon: Unranked) from Corporate Health (🌱 Long-Term Horizon: Locked — Pro). The 4-factor cross-sectional model answers “Where does this stock rank market-wide for tactical momentum & swing alpha?” (synchronizing with /picks), while the 6-factor fundamental model answers “Is this company's standalone balance sheet and operating margin elite for multi-year equity compounding?”
Institutional Valuation Anchors: In Health Care, Biotech & Pharmaceuticals, institutional capital anchors primarily on Pipeline Probability-Adjusted NPV & Forward P/E and Cash Runway (>24 Months for Biotech).
Turn This Divergence Into an Actionable Edge:HUM Decision Playbook
When Vantage's quant engine and Wall Street targets diverge across HUM (Grade C-), standard buy/sell rules fail. Alpha Pro delivers the exact institutional playbook calibrated to Health Care, Biotech & Pharmaceuticals market dynamics.
Specific entry and exit levels tied to institutional support bands and cycle milestones.
Separate execution strategies for intraday momentum, 2–6 week swings, and 12-month core investing.
Instant warnings when trailing solvency penalties trigger fundamental downgrade risk.